More prominent muscle involvement in patients with dermatomyositis with anti-Mi2 autoantibodies
- 5 November 2019
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 93 (19), e1768-e1777
- https://doi.org/10.1212/wnl.0000000000008443
Abstract
Objective To define the clinical phenotype of dermatomyositis (DM) with anti-Mi2 autoantibodies. Methods In this longitudinal cohort study, the prevalence and severity of clinical features at disease onset and during follow-up in patients with anti-Mi2-positive DM were compared to patients with anti-Mi2-negative DM, antisynthetase syndrome (AS), and immune-mediated necrotizing myopathy (IMNM). Longitudinal anti-Mi2 autoantibody titers were assessed. Results A total of 58 patients with anti-Mi2-positive DM, 143 patients with anti-Mi2-negative DM, 162 patients with AS, and 170 patients with IMNM were included. Among patients with anti-Mi2-positive DM, muscle weakness was present in 60% at disease onset and occurred in 98% during longitudinal follow-up; fewer patients with anti-Mi2-negative DM developed weakness (85%; p = 0.008). Patients with anti-Mi2-positive DM were weaker and had higher creatine kinase (CK) levels than patients with anti-Mi2-negative DM or patients with AS. Muscle biopsies from patients with anti-Mi2-positive DM had prominent necrosis. Anti-Mi2 autoantibody levels correlated with CK levels and strength (p < 0.001). With treatment, most patients with anti-Mi2-positive DM had improved strength and CK levels; among 10 with multiple serum samples collected over 4 or more years, anti-Mi2 autoantibody titers declined in all and normalized in 3, 2 of whom stopped immunosuppressant treatment and never relapsed. Patients with anti-Mi2-positive DM had less calcinosis (9% vs 28%; p = 0.003), interstitial lung disease (5% vs 16%; p = 0.04), and fever (7% vs 21%; p = 0.02) than did patients with anti-Mi2-negative DM. Conclusions Patients with anti-Mi2-positive DM have more severe muscle disease than patients with anti-Mi2-negative DM or patients with AS. Anti-Mi2 autoantibody levels correlate with disease severity and may normalize in patients who enter remission.This publication has 18 references indexed in Scilit:
- Antibody levels correlate with creatine kinase levels and strength in anti–3‐hydroxy‐3‐methylglutaryl‐coenzyme A reductase–associated autoimmune myopathyArthritis & Rheumatism, 2012
- Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C‐HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF‐36), Child Health Questionnaire (CHQ), Physician Global Damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index‐2 (FI‐2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI)Arthritis Care & Research, 2011
- Usefulness of anti‐p155 autoantibody for diagnosing cancer‐associated dermatomyositis: A systematic review and meta‐analysisArthritis & Rheumatism, 2011
- Analysis of dermatomyositis‐specific autoantibodies and clinical characteristics in Japanese patientsThe Journal of Dermatology, 2011
- Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathyArthritis & Rheumatism, 2011
- Clinical Correlations With Dermatomyositis-Specific Autoantibodies in Adult Japanese Patients With DermatomyositisArchives of Dermatology, 2011
- Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathyArthritis & Rheumatism, 2010
- Anti–Jo‐1 antibody levels correlate with disease activity in idiopathic inflammatory myopathyArthritis & Rheumatism, 2007
- Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2 antigenAnnals Of The Rheumatic Diseases, 2006
- Prevalence and clinical characteristics of anti-Mi-2 antibodies in Japanese patients with dermatomyositisJournal of Dermatological Science, 2005